mAbsolve

Executive Summary

mAbsolve is a UK-based biotechnology company developing a novel Fc variant that achieves superior silencing of antibody effector functions compared to existing technologies, including LALA, LALAPG, and aglycosylated formats. For approximately 50% of antibody and Fc fusion proteins in clinical development, Fc effector function is not required and can even cause adverse effects. mAbsolve's technology addresses this unmet need by providing a universally silenced Fc backbone that reduces the risk of off-target immune activation, improves safety, and potentially expands the therapeutic window for antibody-based drugs. The platform builds on 40 years of antibody engineering innovation and offers a plug-and-play solution for developers seeking to eliminate Fc-mediated activities without compromising other properties. As a preclinical-stage company, mAbsolve's value proposition hinges on successful validation and partnering. The technology could enhance the safety and efficacy of antibodies in non-depleting applications, such as agonistic receptors, immunomodulation, and antibody-drug conjugates. However, the competitive landscape includes established silenced Fc variants and alternative approaches like Fab fragments or bispecifics. Key risks include manufacturing scalability, intellectual property protection, and adoption by larger pharma partners. With a lean team and no disclosed funding rounds, the company likely requires near-term financing to advance into in vivo studies and secure collaborations.

Upcoming Catalysts (preview)

• Q2 2027Lead Optimization and In Vivo Proof-of-Concept Data60% success
• Q4 2026Strategic Partnership or Licensing Deal with Mid-to-Large Pharma40% success
• Q3 2026Series A Financing Round to Advance Pipeline70% success